All posts by peferguson

MOC-31

MOC-31 is a glycoprotein on the cell-membrane (epithelial glycoprotein 2/epithelial cell adhesion molecule – Ep-CAM) that is widely distributed on epithelial cells and tumor cells.  MOC-31 is often used to differentiate adenocarcinoma (93% positive) from mesothelioma (93% negative).  Other tumors also typically negative for MOC-31 include:  hepatocellular carcinoma (HCC), germ cell tumors, and renal cell (some report up to 50%+) carcinomas.  Some tumors may have characteristic staining patterns (e.g. membraneous vs. cytoplasmic or apical).


Continue reading MOC-31

JAK2, CALR, & MPL Testing in Myeloproliferative Neoplasms (MPN)

Molecular Testing Specimen Adequacy Summary
  • JAK2, CALR, and MPL testing is often performed on peripheral blood specimens in an outpatient setting.
  • JAK2 mutations are preferably analyzed in granulocytes.
  • Peripheral blood and bone marrow specimens are equally adequate for the identification of JAK2 mutations.
  • By extrapolation, CALR and MPL testing on peripheral blood specimens should be equally adequate.

Continue reading JAK2, CALR, & MPL Testing in Myeloproliferative Neoplasms (MPN)

Extranodal Marginal Zone Lymphoma of Mucosal Associated Lymphoid Tissue (MALT Lymphoma)

Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) involves extra nodal tissue and shows infiltration of the marginal zones and inter follicular regions. 
  • Gastric MALT is associated with H. pylori infection in up to 90% of cases. 
  • MALT in the thyroid has been associated with Hashimoto’s thyroiditis (~20% of cases).
  • Ocular MALT lymphomas have been associated with various infections.

Continue reading Extranodal Marginal Zone Lymphoma of Mucosal Associated Lymphoid Tissue (MALT Lymphoma)

Plasmablastic Lymphoma

Immunophenotypic Expression Pattern
Marker
Comment
Negative
Weak/Negative
Weak/Negative
Negative
Positive
Variable
Positive (Usually)
Negative (Usually)
Positive
Rare + case
References
Parker, A., et. al.  “Best Practice in Lymphoma Diagnosis and Reporting.”  British Committee for Standards in Haematology, Royal College of Pathologists.  April, 2010.